Clinical Trial Update: Anti-GD2 ADC M3554 in Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial of the anti-GD2 antibody-drug conjugate M3554 for advanced solid tumors is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• M3554

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: Advanced Solid Tumor | Phase 1 | Status: RECRUITING